Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Q3 Earnings Rundown: Eisai, Takeda, Ono, and More
February 5, 2019
- Ichiro Watanabe to Head Up Teijin Pharma
February 5, 2019
- Oropharyngeal Candidiasis Drug Oravi Now Available in Japan
February 4, 2019
- Takeda Drops US Filing for Ninlaro Label Expansion, Plans Resubmission with OS Data
February 4, 2019
- Keytruda Beats Opdivo in Q4 Global Sales including Asia
February 4, 2019
- Sawai and 7 Other Generic Makers Seeking Lyrica Patent Invalidity
February 4, 2019
- Chugai Plays It Safe with New 3-Year Plan on Consecutive Re-Pricing, Eyes 7-9% Annual EPS Growth
February 1, 2019
- Oncolys Plans to Begin Japan PII Study of Oncolytic Virus in 2nd Half of 2019
February 1, 2019
- Chugai Renews Record Earnings in 2018 on New Drugs, Exports
February 1, 2019
- Daiichi Sankyo Selling Takatsuki Plant to Taiyo for 37.6 Billion Yen
February 1, 2019
- Ono Grabs Asian Rights to Repare’s Pol-theta Inhibitor
February 1, 2019
- JT Files Topical JAK Inhibitor in Japan for Atopic Dermatitis
February 1, 2019
- FDA Nixes Sunovion’s Parkinson’s Drug, but Requires No New Studies
February 1, 2019
- Fycompa Filed for Monotherapy, Pediatric Use in Japan: Eisai
January 31, 2019
- Merck Serono Files Bavencio in Japan for First-Line Use in RCC
January 31, 2019
- Takeda’s Tetravalent Dengue Vaccine Succeeds in PIII Study
January 31, 2019
- Chugai to Transfer Japan Rights for 3 Topical Maxacalcitol Products to Maruho
January 31, 2019
- Kymriah Study Drugs to Be Manufactured in Kobe: Novartis
January 30, 2019
- Stem Cell Therapy SB623 Misses Key Target in US PIIb Study for Stroke: SanBio, Sumitomo Dainippon
January 30, 2019
- Protosera, Fujita Health Univ. Tie Up for Research to Develop Treatments for Autism Spectrum Disorder
January 30, 2019
ページ
Chugai Pharmaceutical’s Duchenne muscular dystrophy (DMD) gene therapy Elevidys has finally reached the Japanese market after months of safety reviews…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…